Company intelligence / Profile preview

Sino-cell Biomed

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Sino-Cell Biomed is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on addressing unmet needs in hematological oncology, particularly through the development of multi-targeted CAR-T products designed to prevent relapse and improve efficacy. Its lead candidate is a dual-targeted CD19/CD22 CAR-T therapy currently in Phase 2 clinical trials for B-cell malignancies. Sino-Cell Biomed integrates research, clinical development, and manufacturing to accelerate the delivery of cell-based medicines to patients.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on Sino-cell Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sino-cell Biomed.

Explore the full profile